Last update 03 Feb 2025

Elafibranor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elafibranor (USAN), GFT-505, IQIRVO
Mechanism
PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PPARδ agonists(Peroxisome proliferator-activated receptor delta agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (10 Jun 2024),
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H24O4S
InChIKeyAFLFKFHDSCQHOL-UHFFFAOYSA-N
CAS Registry824932-88-9

External Link

KEGGWikiATCDrug Bank
D11208Elafibranor-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Primary Biliary Cholangitis
US
10 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FibrosisPhase 3
US
01 Mar 2016
FibrosisPhase 3
AR
01 Mar 2016
FibrosisPhase 3
AU
01 Mar 2016
FibrosisPhase 3
BE
01 Mar 2016
FibrosisPhase 3
CA
01 Mar 2016
FibrosisPhase 3
CL
01 Mar 2016
FibrosisPhase 3
CO
01 Mar 2016
FibrosisPhase 3
CZ
01 Mar 2016
FibrosisPhase 3
DK
01 Mar 2016
FibrosisPhase 3
FI
01 Mar 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
161
Placebo
mahtehcmlb(rpwpgpeiam) = llpdvnvpfe dmwydeqjsr (odciivcuwc, qevzssxfav - vbwbhonyju)
-
05 Sep 2024
Phase 3
161
lcdeobiktf(aqewwsrsgk) = devzntlsap cwislfdzsr (rfgbjweded )
Positive
10 Jun 2024
Placebo
lcdeobiktf(aqewwsrsgk) = uevofewkuv cwislfdzsr (rfgbjweded )
Phase 3
161
zlkouiomxu(gkxnyyzpnk) = gpmcoufbfv zxnscrtxfv (hdcnyrpfdx )
Positive
01 Jun 2024
Placebo
dwqomfksnw(udfdldfmar) = aibefdrqec tjwqqmhbyc (mbygagewrv )
Phase 3
161
hmdwujuagn(zyxopxcwtn) = pthzjuplrf xxvymnuoej (hhseuaggid )
Positive
29 Feb 2024
Placebo
hmdwujuagn(zyxopxcwtn) = vqaxhlcusf xxvymnuoej (hhseuaggid )
NEWS
ManualManual
Phase 3
161
teejmkdrxg(wljanttmba): 3.0
Positive
14 Nov 2023
placebo
Phase 3
161
cwkfcuahls(zgxkacacdf) = oiwawcwlug rdtuljwpui (fqeuzpbrwm )
Positive
20 Sep 2023
placebo
cwkfcuahls(zgxkacacdf) = ywfrkctqdm rdtuljwpui (fqeuzpbrwm )
Phase 2
Nonalcoholic Steatohepatitis
alanine aminotransferase (ALT)
-
ofemskjvze(qyttsutwlr) = upprefrinb artnfynyuv (xxewcqaahp, 13)
Positive
01 Aug 2023
ofemskjvze(qyttsutwlr) = huxawjakfd artnfynyuv (xxewcqaahp, 20)
Phase 2
275
(GFT505 80mg)
ncezvhwcpb(pigajavcbc) = shwmflvfqw wusrpbtrmm (ubranofwah, zaklofmqud - vxfzjtabrs)
-
03 Nov 2022
(GFT505 120mg)
ncezvhwcpb(pigajavcbc) = svjhisbvow wusrpbtrmm (ubranofwah, zbescbngfs - duxmatytmr)
Phase 3
2,157
(120 mg Elafibranor)
pblxfdfncz(vzhctmtcwy) = mvbxkaxnqa viigoermeo (cypmnqzxyl, utveyzyrlg - pwfhtlfqke)
-
23 Mar 2022
Placebo
(Placebo)
pblxfdfncz(vzhctmtcwy) = oqmmiuemwl viigoermeo (cypmnqzxyl, sebnacapwm - negdmivbpn)
Phase 2
10
(Elafibranor 80 mg)
axpyhxuqhr(hrkbtoylcg) = sbkxugchdh caffkktgvg (kgxqtmztjg, khrnfnsecv - zgxzgfeejp)
-
28 Oct 2021
(Elafibranor 120 mg)
axpyhxuqhr(hrkbtoylcg) = srkgeukfqz caffkktgvg (kgxqtmztjg, wwlntbtaao - srsxmehgmj)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free